This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

B. A. Sachais, PhD; J. N. Logue, MPH
Medical Dept Pharmaceuticals Div CIBA-GEIGY Corp Summit, NJ 07901

Arch Neurol. 1977;34(11):722.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

The results reported in our publication were a balanced reflection of those obtained from all multiple sclerosis patients involved in a multicenter, controlled trial of baclofen vs placebo. Since, as mentioned in the article, a standardized method of clinical measurement of the various signs and symptoms involved is not available, a variety of assessments and measurements were employed.

Some of these, by necessity, were quite subjective in nature and, therefore, easily criticized. One cannot, however, use specialized neurophysiological techniques in such a broadbased clinical trial employing primarily clinically oriented investigators and centers. Therefore, we can, at best, attempt to rate those signs and symptoms considered clinically significant by such clinicians.

Although the meaning of "diluting the beneficial effects of the drug" is not quite clear from Dr Young's letter, we believe that all results should have been and were reported. Furthermore, improvement in such key symptoms as frequency of flexor . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?